Rhodia : Rhodia / CTI Inc Agreement for the use of rare earths in state-of-the-art medical imaging


	Rhodia / CTI Inc Agreement for the use of rare earths in state-of-the-art medical imaging
	about : medical imaging, siemens medical, heart disease, rare earths, molecular medicine, siemens medical systems, rare earth


	medical imaging rare earths rare earth paris bourse new york stock exchange stock exchange leading supplier

Rhodia / CTI Inc Agreement for the use
of rare earths in state-of-the-art medical imaging

Paris, June 21, 2000 – Rhodia and CTI have signed a development and supply agreement covering the use of a rare-earth compound in the new generation of medical imaging devices based on PET technology (Positron Emission Tomography). This agreement illustrates the strategy of Rhodia Rare Earths to develop, in partnership with its customers, added-value specialty products.

The principle of PET is based on recording the emissions of an intravenously-injected tracer. In addition to acting as a direct indicator of the biochemical and functional activity of body organs, PET provides images showing their dynamic functioning.

Originally applied to the study of the brain, PET is now successfully used in early detection of cancer, allowing more rapid and adapted treatment. It is also successfully used for various diagnostic applications such as heart disease and brain disorders.

Rhodia Rare Earths is the leading worldwide manufacturer of rare earth salts and oxides used edantic!) in automotive emissions control, material coloration, glass polishing, chemicals, electronics, luminescence and medical imaging.

CTI Inc. is the leading supplier of products and services for positron emission tomography (PET) which allows the early detection, diagnosis, and therapy planning of cancer and other diseases utilizing molecular medicine techniques. CTI products are distributed worldwide through Siemens Medical Systems. Founded in 1983, CTI is a privately held corporation headquartered in Knoxville, Tennessee – USA.

Rhodia, one of the world leaders in specialty chemicals, contributes to improving the quality of life by developing value-added products, services and solutions for the beauty, clothing, foodstuffs and healthcare markets as well as for the environment, transport and industry. Rhodia employs 24,800 people worldwide and recorded sales of 5,525 million Euros in 1999. Rhodia is listed on the Paris Bourse and the New York stock exchange.

Contacts

Press Relations
Jean-Christophe Huertas
Tel : +33 1 55 38 42 51

Investor Relations
Angélina Palus
Tel : +33 1 55 38 42 99